Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alpha Cognition Inc.ACOG · Entity 6339 | Director | August 21, 2026 | August 24, 2026 |
| Milestone Pharmaceuticals Inc.MIST · Entity 6561 | Director | June 10, 2026 | June 12, 2026 |
| Oncternal Therapeutics, Inc.ONCT · Entity 89585 | Director | June 20, 2024 | June 24, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alpha Cognition Inc.
Report date August 21, 2026 · Filed August 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 32,241 |
Reported balance
After 2026-08-21 transaction · row 1
1 source rowRow 1 · 2026-08-21 · Purchase · Acquired 10,000 · Balance 32,241 |
Milestone Pharmaceuticals Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2036-06-10 | Direct | 77,000 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 77,000 · Balance 77,000 F1: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date.
Oncternal Therapeutics, Inc.
Report date June 20, 2024 · Filed June 24, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $8.10 · Expires 2034-06-20 | Direct | 2,200 |
Reported balance
After 2024-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-20 · Grant · Acquired 2,200 · Balance 2,200 F1: One-twelfth of the number of shares subject to the option vest and become exercisable in substantially equal installments on each monthly anniversary of the grant date, subject to the Reporting Person's continued service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-twelfth of the number of shares subject to the option vest and become exercisable in substantially equal installments on each monthly anniversary of the grant date, subject to the Reporting Person's continued service through such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CymaBay Therapeutics, Inc.
Report date March 22, 2024 · Filed March 22, 2024
Section 16 reporting ended · disclosed 2024-03-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 1
1 source rowRow 1 · 2024-03-22 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024 (the "Merger Agreement"), by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding share of CymaBay common stock was converted into the right to receive a cash payment equal to $32.50, less applicable withholding taxes. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.90 · Expires 2025-04-15 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-03-22 · Disposition to issuer · Disposed 18,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.04 · Expires 2025-10-05 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-22 · Disposition to issuer · Disposed 25,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.72 · Expires 2026-06-27 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-03-22 · Disposition to issuer · Disposed 9,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.48 · Expires 2027-04-26 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-03-22 · Disposition to issuer · Disposed 27,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.50 · Expires 2027-06-27 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-03-22 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.47 · Expires 2027-09-21 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-03-22 · Disposition to issuer · Disposed 7,500 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.69 · Expires 2028-01-23 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-03-22 · Disposition to issuer · Disposed 16,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.43 · Expires 2029-01-28 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-03-22 · Disposition to issuer · Disposed 27,705 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.05 · Expires 2030-05-14 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2024-03-22 · Disposition to issuer · Disposed 49,245 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.78 · Expires 2031-01-25 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2024-03-22 · Disposition to issuer · Disposed 32,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.94 · Expires 2032-01-24 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2024-03-22 · Disposition to issuer · Disposed 67,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2033-01-24 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2024-03-22 · Disposition to issuer · Disposed 25,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.85 · Expires 2034-01-23 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2024-03-22 · Disposition to issuer · Disposed 14,010 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024 (the "Merger Agreement"), by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding share of CymaBay common stock was converted into the right to receive a cash payment equal to $32.50, less applicable withholding taxes.
F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 22, 2017 Filed Sep 26, 2017 09:40 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $7.47 | $0.00 |
DisclosureSEC source: 0001209191-17-053903 · doc4.xml · derivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2027-09-21 F1 · derivative.exercise_date: The shares subject to the option shall vest in 12 equal monthly installments commencing on June 1, 2017, subject to the Reporting Person's continuous service to the Issuer as of each such date. The option allows for early exercise by the Reporting Person. Read SEC document |
| August 01, 2017 Filed Aug 2, 2017 08:21 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | PurchaseCommon Stock | 3,500 | $6.85 | $23,964.50 |
DisclosureSEC source: 0001209191-17-047016 · doc4.xml · nonDerivative · entry 4 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Read SEC document |
| August 01, 2017 Filed Aug 2, 2017 08:21 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | PurchaseCommon Stock | 1,000 | $6.84 | $6,839.00 |
DisclosureSEC source: 0001209191-17-047016 · doc4.xml · nonDerivative · entry 3 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,500 Read SEC document |
| August 01, 2017 Filed Aug 2, 2017 08:21 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | PurchaseCommon Stock | 300 | $6.84 | $2,051.40 |
DisclosureSEC source: 0001209191-17-047016 · doc4.xml · nonDerivative · entry 2 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,500 Read SEC document |
| August 01, 2017 Filed Aug 2, 2017 08:21 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | PurchaseCommon Stock | 200 | $6.83 | $1,365.80 |
DisclosureSEC source: 0001209191-17-047016 · doc4.xml · nonDerivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,200 Read SEC document |
| June 28, 2017 Filed Jun 30, 2017 14:47 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001042074-17-000015 · primary_doc.xml · derivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-27 F1 · derivative.exercise_date: The shares subject to the option shall vest in 12 equal monthly installments commencing on June 1, 2017. Read SEC document |
| April 27, 2017 Filed May 1, 2017 19:50 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantStock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $3.48 | $0.00 |
DisclosureSEC source: 0001179110-17-006331 · edgar.xml · derivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2027-04-26 F1 · derivative.exercise_date: The option vests in equal monthly installments over the eight-month period beginning on the vesting commencement date of April 15, 2017, subject to the Reporting Person's continuous service to the Issuer; provided, however, that this option will stop vesting on the date the Reporting Person resigns as the Executive Chairman of the Issuer, but continue to serve as the director of the Issuer. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 16:56 UTC | Oncternal Therapeutics, Inc. GTXI · Entity 89585 | GrantEmployee Stock Option (Right to Buy) · Derivative | 95,000 | $0.00 Strike: $4.71 | $0.00 |
DisclosureSEC source: 0001179110-17-003651 · edgar.xml · derivative · entry 1 Wills Robert James · CIK 0001634189 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2027-02-27 F1 · derivative.exercise_date: The option vests and is exercisable in 3 equal annual installments beginning February 28, 2020. Read SEC document |
| October 14, 2016 Filed Oct 17, 2016 16:17 UTC | Oncternal Therapeutics, Inc. GTXI · Entity 89585 | GrantCommon Stock | 123,456 | $0.81 | $99,999.36 |
DisclosureSEC source: 0001179110-16-030747 · edgar.xml · nonDerivative · entry 1 Wills Robert James · CIK 0001634189 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,323,456 Read SEC document |
| September 06, 2016 Filed Sep 9, 2016 08:05 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | PurchaseCommon Stock | 25,000 | $2.43 | $60,857.50 |
DisclosureSEC source: 0001179110-16-029465 · edgar.xml · nonDerivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.37 to $2.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.